ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,099.96
      1.02%
      US Tech 100
      17,244.00
      1.57%
      Dow Jones
      38,239.66
      0.40%
      Brent Oil
      88.165
      0.00%
      Bitcoin
      63,040.52
      -1.10%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Canada
      5. NEO
      6. Abbvie CDR (ABBV)

      7. Abbvie CDR (ABBV) News

      ABBV

      Abbvie CDR (ABBV)

      		Date:
      Sort by:
       Showing the most relevant articles for your search:NYSE:ABBV
      DateTimeSourceHeadlineSymbolCompany
      04/26/20247:47AMIH Market NewsU.S. Futures Climb in Pre-Market Trading Amid Tech Gains and Upcoming Inflation DataNYSE:ABBVAbbVie Inc
      04/26/20247:35AMPR Newswire (US)AbbVie Reports First-Quarter 2024 Financial ResultsNYSE:ABBVAbbVie Inc
      04/25/20248:00AMPR Newswire (US)New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis StudyNYSE:ABBVAbbVie Inc
      04/23/20248:00AMPR Newswire (US)Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest BrandsNYSE:ABBVAbbVie Inc
      04/18/20248:31AMPR Newswire (US)Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell ArteritisNYSE:ABBVAbbVie Inc
      04/12/20247:30AMPR Newswire (US)AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of MigraineNYSE:ABBVAbbVie Inc
      04/09/20248:00AMPR Newswire (US)SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to AcneNYSE:ABBVAbbVie Inc
      04/04/20248:00AMPR Newswire (US)AbbVie to Host First-Quarter 2024 Earnings Conference CallNYSE:ABBVAbbVie Inc
      04/03/20248:30AMPR Newswire (US)Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting®NYSE:ABBVAbbVie Inc
      04/01/20247:50AMGlobeNewswire Inc.NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-YearNYSE:ABBVAbbVie Inc
      03/26/20247:20AMIH Market NewsSuper Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest NewsNYSE:ABBVAbbVie Inc
      03/25/202411:00AMPR Newswire (US)Allergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in AestheticsNYSE:ABBVAbbVie Inc
      03/25/20248:31AMPR Newswire (US)AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesNYSE:ABBVAbbVie Inc
      03/25/20248:30AMGlobeNewswire Inc.AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesNYSE:ABBVAbbVie Inc
      03/22/20243:02PMPR Newswire (US)U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer PatientsNYSE:ABBVAbbVie Inc
      03/21/20248:00AMPR Newswire (US)ALLERGAN AESTHETICS CONTINUES TO CHAMPION INDIVIDUALITY, DRIVE INNOVATION AND LEAD WITH INTEGRITY AS IT HOSTS EXPERT LED SYMPOSIA AT AMWC 2024NYSE:ABBVAbbVie Inc
      03/07/20248:00AMPR Newswire (US)AbbVie to Present at the Barclays 26th Annual Global Healthcare ConferenceNYSE:ABBVAbbVie Inc
      03/06/20248:03AMPR Newswire (US)AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics PortfoliosNYSE:ABBVAbbVie Inc
      03/05/20245:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
      03/05/202412:09PMPR Newswire (Canada)Dragonfly a reçu un paiement d'étape à la suite de la prise de dose du premier patient à l'essai clinique de phase 1 d'AbbVie évaluant le DF4101/ABBV-303NYSE:ABBVAbbVie Inc
      03/05/20248:00AMPR Newswire (US)JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA ApprovalNYSE:ABBVAbbVie Inc
      03/05/20247:00AMPR Newswire (US)Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303NYSE:ABBVAbbVie Inc
      03/05/20247:00AMPR Newswire (Canada)Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303NYSE:ABBVAbbVie Inc
      03/05/20247:00AMPR Newswire (US)Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303NYSE:ABBVAbbVie Inc
      03/01/20247:53PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:ABBVAbbVie Inc
      03/01/20245:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
      03/01/20245:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
      03/01/20245:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
      03/01/20245:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
      03/01/20245:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
       Showing the most relevant articles for your search:NYSE:ABBV